换一批
换一批Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
第一作者：
Robert J,Motzer
第一单位：
Department of Medicine, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
作者：
主题词
成年人(Adult);血管生成抑制剂(Angiogenesis Inhibitors);血管生成素2(Angiopoietin-2);抗原, 肿瘤(Antigens, Neoplasm);碳酸酐酶类(Carbonic Anhydrases);癌, 肾细胞(Carcinoma, Renal Cell);无病生存(Disease-Free Survival);用药计划表(Drug Administration Schedule);药物监测(Drug Monitoring);药物筛选试验, 抗肿瘤(Drug Screening Assays, Antitumor);女(雌)性(Female);人类(Humans);缺氧诱导因子1, α亚基(Hypoxia-Inducible Factor 1, alpha Subunit);吲哚类(Indoles);肾肿瘤(Kidney Neoplasms);男(雄)性(Male);基质金属蛋白酶2(Matrix Metalloproteinase 2);多态性, 单核苷酸(Polymorphism, Single Nucleotide);预后(Prognosis);吡咯类(Pyrroles);治疗结果(Treatment Outcome);血管内皮生长因子A(Vascular Endothelial Growth Factor A);血管内皮生长因子受体3(Vascular Endothelial Growth Factor Receptor-3);脑视网膜血管瘤抑制蛋白质(Von Hippel-Lindau Tumor Suppressor Protein)
DOI
10.1007/s00280-014-2539-0
PMID
25100134
发布时间
2022-03-16
- 浏览30
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
